Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potentially thrombogenic materials in factor IX concentrates.

H S Kingdon, R L Lundblad, J J Veltkamp

    Thrombosis Et Diathesis Haemorrhagica
    |June 30, 1975
    PubMed
    Summary

    Factor IX concentrates derived from human plasma may pose thrombogenic risks. Studies found significant levels of thrombogenic enzymes in many Factor IX products, necessitating careful therapeutic consideration.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Dietary assessment can be based on pattern recognition rather than recall.

    Medical hypotheses·2020
    Same author

    Actions of thrombin in the interstitium.

    Journal of thrombosis and haemostasis : JTH·2015
    Same author

    Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics.

    Vox sanguinis·2007
    Same author

    Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.

    American journal of hematology·2004
    Same author

    von Willebrand factor-cleaving protease content of Cohn plasma fractions.

    Vox sanguinis·2003
    Same author

    Approach to assay validation for the development of biopharmaceuticals.

    Biotechnology and applied biochemistry·2002

    Area of Science:

    • Hematology
    • Biochemistry
    • Pharmacology

    Background:

    • Factor XI concentrates, used therapeutically, have raised concerns regarding potential thrombogenicity.
    • Assessing the thrombogenic potential of these plasma-derived products is crucial for patient safety.

    Purpose of the Study:

    • To evaluate and quantify potentially thrombogenic materials in Factor XI concentrates.
    • To compare in vitro and in vivo assay results for thrombogenicity.

    Main Methods:

    • In vitro and in vivo assays were performed to detect and quantify thrombogenic materials.
    • Various Factor XI concentrate batches were tested and ranked based on detected thrombogenic levels.
    • Correlation analysis was conducted between in vivo and in vitro assays, and antithrombin III content.

    Main Results:

    • A significant correlation (r=0.77) was observed between in vivo and in vitro assays for thrombogenicity in Factor XI concentrates lacking heparin.
    • No correlation was found between thrombogenicity assays and antithrombin III levels.
    • Many available Factor XI concentrates were found to contain substantial amounts of thrombogenic enzymes.

    Conclusions:

    • Factor XI concentrates contain potentially thrombogenic enzymes, posing a risk for therapeutic use.
    • The presence of these thrombogenic factors requires careful consideration before administering Factor XI concentrates.
    • Further research may be needed to develop safer Factor XI concentrate formulations.

    Related Experiment Videos